Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

辉瑞公司（纽约证券交易所代码：PFE）今天宣布，已与领先的中国生物制药公司三生制药（股票代码：01530.HK）就双特异性抗体SSGJ-707的开发、生产和商业化达成了一项独家的全球（除中国外）许可协议。SSGJ-707靶向PD-1和VEGF，目前该药物正在中国进行多项临床试验，适应症包括非小细胞肺癌、转移性结直肠癌和妇科肿瘤。

SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines. 3SBio plans to initiate the first Phase 3 study in China in 2025..

SSGJ-707 在一类前景广阔的癌症药物中展示了初步的有效性和安全性数据。三生制药计划于2025年在中国开展首个三期研究。

Under the terms of the agreement, 3SBio and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd. will grant Pfizer an exclusive global license to develop, manufacture and commercialize SSGJ-707 worldwide, excluding China. The agreement also provides Pfizer the option of commercialization rights in China.

根据协议条款，三生制药及其子公司沈阳阳光制药有限公司和三生国健药业（上海）有限公司将授予辉瑞在全球（不包括中国）开发、生产和商业化SSGJ-707的独家全球许可。该协议还赋予辉瑞在中国的商业化权利选择权。

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion as well as tiered double-digit royalties on sales of SSGJ-707, if approved..

三生国健将获得12.5亿美元的预付款，并有资格获得高达48亿美元的与某些开发、监管和商业里程碑相关的里程碑付款，以及SSGJ-707获批后的销售阶梯式两位数专利税。

The transaction is expected to close in the third quarter subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and 3SBio shareholder approval. Upon close, Pfizer will make a $100 million equity investment in 3SBio subject to an agreed upon securities subscription agreement between the parties.

该交易预计将在第三季度完成，但须满足惯例的交割条件，包括获得所需的监管批准和三生制药股东的批准。交易完成后，辉瑞将根据双方约定的证券认购协议，向三生制药进行1亿美元的股权投资。

Pfizer plans to manufacture drug substance for SSGJ-707 in Sanford, North Carolina, and drug product in McPherson, Kansas..

辉瑞计划在北卡罗来纳州的桑福德生产SSGJ-707的药物成分，并在堪萨斯州的麦克弗森生产药物制剂。

About Pfizer Oncology

辉瑞肿瘤事业部简介

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics.

在辉瑞肿瘤学，我们正处于癌症治疗新时代的前沿。我们行业领先的资产组合和广泛的管线包括三种核心作用机制，从多个角度攻击癌症，包括小分子、抗体药物偶联物 (ADC) 和双特异性抗体，以及其他免疫肿瘤学生物制品。

We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives..

我们专注于在一些全球最常见的癌症中提供变革性的治疗方法，包括乳腺癌、泌尿生殖系统癌症、血液肿瘤学以及包含肺癌在内的胸部癌症。受科学驱动，我们致力于加速突破，以帮助癌症患者过上更好、更长寿的生活。

About Pfizer: Breakthroughs That Change Patients’ Lives

关于辉瑞：改变患者生活的突破性进展

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

在辉瑞，我们运用科学和全球资源，为人们带来能够延长生命并显著改善生活的疗法。我们努力在医疗保健产品的研发、开发和生产中树立质量、安全性和价值的标准，包括创新药物和疫苗。

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

每天，辉瑞的同事们在发达国家和新兴市场开展工作，推动健康、预防、治疗和攻克当今最令人恐惧的疾病。作为全球首屈一指的创新型生物制药公司之一，我们与医疗保健提供者、政府和当地社区合作，支持并扩大全球范围内对可靠且负担得起的医疗保健的获取机会。

For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at .

175 年来，我们一直努力为所有依赖我们的人带来改变。我们会定期在网站上发布可能对投资者重要的信息。